On July 16, Lu Pengqi, Deputy Commissioner of the China National Intellectual Property Administration (CNIPA), met with Kevin Haninger, Vice President of the Pharmaceutical Research and Manufacturers of America (PhRMA), and his delegation in Beijing. The two sides had an in-depth exchange on China's laws, regulations, and policy measures regarding pharmaceutical intellectual property (IP) protection.

Lu emphasized that the Chinese government has been attaching great importance to IP protection and upholding equal protection for the IP of both domestic and foreign-funded enterprises. In recent years, China has continuously improved its laws and regulations, and related systems, which will provide greater support for the IP protection of both Chinese and foreign pharmaceutical companies. The CNIPA is willing to listen to different voices to promote the establishment of a more equitable, open, and transparent innovation and market environment.

Haninger expressed appreciation for the progress China has made in pharmaceutical IP protection in recent years, shared his views and suggestions on specific policies, and hoped to continue deepening exchanges with Chinese IP authorities.

CNIPA principal officials responsible for relevant departments attended the meeting.(Translated from CNIPA Website Chinese Version)